(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.
The broker said Hikma had recently provided mid-term guidance that "reflects growing optimism about the Rx and injectables businesses".

It continued: "This adds to the positive outlook for the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE